Plate-based diversity subset screening: an efficient paradigm for high throughput screening of a large screening file
详细信息 查看全文
- 作者：Andrew S. Bell (1) (2)
Joseph Bradley (1) (3)
Jeremy R. Everett (1) (4)
Michelle Knight (1) (5)
Jens Loesel (1) (6)
John Mathias (1) (7)
David McLoughlin (1) (8)
James Mills (1) (9)
Robert E. Sharp (10) (11)
Christine Williams (1) (12)
Terence P. Wood (1) (13) - 关键词：Rule of 40 (Ro40) ; High throughput screening (HTS) ; Plate based ; Diversity ; Subset ; Screening file
- 刊名：Molecular Diversity
- 出版年：2013
- 出版时间：May 2013
- 年：2013
- 卷：17
- 期：2
- 页码：319-335
- 全文大小：804KB
- 参考文献：1. Scannell JW, Blanckley A, Boldon H, Warrington B (2012) Diagnosing the decline in pharmaceutical R &D efficiency. Nat Rev Drug Discovery 11:191鈥?00. doi:
2. Pammolli F, Magazzini L, Riccaboni M (2011) The productivity crisis in pharmaceutical R &D. Nat Rev Drug Discovery 10:428鈥?38. doi:
3. Mullard A (2012) 2011 FDA drug approvals. Nat Rev Drug Discovery 11:91鈥?4. doi:
4. Munos B (2009) Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discovery 8:959鈥?68. doi:
5. Pereira DA, Williams JA (2007) Origin and evolution of high throughput screening. Br J Pharmacol 152:53鈥?1. doi:
6. H眉ser J (2006) High-throughput screening in drug discovery. Wiley-VCH, Weinheim p://dx.doi.org/10.1002/3527609326">CrossRef
7. Macarron R, Banks MN, Bojanic D, Burns DJ, Cirovic DA, Garyantes T, Green DV, Hertzberg RP, Janzen WP, Paslay JW, Schopfer U, Sittampalam GS (2011) Impact of high-throughput screening in biomedical research. Nat Rev Drug Discovery 10:188鈥?95. doi:
8. Mayr LM, Bojanic D (2009) Novel trends in high-throughput screening. Curr Opin Pharmacol 9:580鈥?88. doi:
9. Bakken GA, Bell AS, Boehm M, Everett JR, Gonzales R, Hepworth D, Klug-McLeod JL, Lanfear J, Loesel J, Mathias J, Wood TP (2012) Shaping a screening file for maximal lead discovery efficiency and effectiveness: elimination of molecular redundancy. J Chem Inf Model 52:2937鈥?949. doi:
10. Xi H, Lunney EA (2011) The design, annotation, and application of a kinase-targeted library. Methods Mol Biol 685:279鈥?91. doi:
11. Yeap SK, Walley RJ, Snarey M, van Hoorn WP, Mason JS (2007) Designing compound subsets: comparison of random and rational approaches using statistical simulation. J Chem Inf Model 47:2149鈥?158. doi:
12. Congreve M, Carr R, Murray C, Jhoti H (2003) A 鈥檙ule of three鈥?for fragment-based lead discovery? Drug Discovery Today 8:876鈥?77 p://dx.doi.org/10.1016/S1359-6446(03)02831-9">CrossRef
13. Posner BA, Xi H, Mills JE (2009) Enhanced HTS hit selection via a local hit rate analysis. J Chem Inf Model 49:2202鈥?210. doi:
14. Soulard P, McLaughlin M, Stevens J, Connolly B, Coli R, Wang L, Moore J, Kuo MS, LaMarr WA, Ozbal CC, Bhat BG (2008) Development of a high-throughput screening assay for stearoyl-CoA desaturase using rat liver microsomes, deuterium labeled stearoyl-CoA and mass spectrometry. Anal Chim Acta 627:105鈥?11. doi:
15. Everett J, Gardner M, Pullen F, Smith G, Snarey M, Terrett N (2001) The application of non-combinatorial chemistry to lead discovery. Drug Discovery Today 6:779鈥?85. doi:
16. Feng BY, Shoichet BK (2006) Synergy and antagonism of promiscuous inhibition in multiple-compound mixtures. J Med Chem 49:2151鈥?154. doi:
17. Bender A, Bojanic D, Davies JW, Crisman TJ, Mikhailov D, Scheiber J, Jenkins JL, Deng Z, Hill WA, Popov M, Jacoby E, Glick M (2008) Which aspects of HTS are empirically correlated with downstream success? Curr Opin Drug Discovery Dev 11:327鈥?37
18. Hajduk PJ, Greer J (2007) A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discovery 6:211鈥?19. doi:
19. Larsson A, Jansson A, Aberg A, Nordlund P (2011) Efficiency of hit generation and structural characterization in fragment-based ligand discovery. Curr Opin Chem Biol 15:482鈥?88. doi:
20. Schneider G (2010) Virtual screening: an endless staircase? Nat Rev Drug Discovery 9:273鈥?76. doi:
21. Hopkins A, Lanfear J, Lipinski C, Beeley L (2005) Chemical tools for indications discovery. Annu Rep Med Chem 40:339鈥?48. doi:
22. Pearlman RS, Smith KM (1998) Novel software tools for chemical diversity. Perspect Drug Discovery Des 9鈥?1:339鈥?53. doi:
23. Crisman TJ, Jenkins JL, Parker CN, Hill WAG, Bender A, Deng Z, Nettles JH, Davies JW, Glick M (2007) 鈥淧late cherry picking鈥? a novel semi-sequential screening paradigm for cheaper, faster, information-rich compound selection. J Biomol Screen 12:320鈥?27. doi:
24. Sukuru SC, Jenkins JL, Beckwith RE, Scheiber J, Bender A, Mikhailov D, Davies JW, Glick M (2009) Plate-based diversity selection based on empirical HTS data to enhance the number of hits and their chemical diversity. J Biomol Screen 14:690鈥?99. doi:
25. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 23:3鈥?5. doi:
26. Blagg J (2006) Structure鈥揳ctivity relationships for in vitro and in vivo toxicity. Annu Rep Med Chem 41:353鈥?68. doi:
27. Spencer RW (1998) High-throughput screening of historic collections: observations on file size, biological targets, and file diversity. Biotechnol Bioeng 61:61鈥?7 p://dx.doi.org/10.1002/(SICI)1097-0290(199824)61:1<61::AID-BIT11>3.0.CO;2-C">CrossRef
28. Milne GM (2003) Pharmaceutical productivity鈥攖he imperative for new paradigms. Annu Rep Med Chem 38:383鈥?96. doi:
29. Leardi R (2001) Genetic algorithms in chemometrics and chemistry: a review. J Chemom 15:559鈥?69. doi:
30. SciTegic/Accelrys (2006) Pipeline Pilot v5.1
31. Leo AJ, Hoekman D (2000) Calculating log P(oct) with no missing fragments: the problem of estimating new interaction parameters. Perspect Drug Discovery Des 18:19鈥?8. doi:
32. Ertl P, Rohde B, Selzer P (2000) Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 43:3714鈥?717. doi:
33. Barnard JM, Downs GM (1997) Chemical fragment generation and clustering software. J Chem Inf Comput Sci 37:141鈥?42. doi:
34. Bemis GW, Murcko MA (1996) The properties of known drugs. 1. Molecular frameworks. J Med Chem 39:2887鈥?893. doi:
35. Priest BT (2009) Future potential and status of selective sodium channel blockers for the treatment of pain. Curr Opin Drug Discovery Dev 12:682鈥?92
36. Deacon M, Singleton D, Szalkai N, Pasieczny R, Peacock C, Price D, Boyd J, Boyd H, Steidl-Nichols JV, Williams C (2007) Early evaluation of compound QT prolongation effects: a predictive 384-well fluorescence polarization binding assay for measuring hERG blockade. J Pharmacol Toxicol Methods 55:238鈥?47. doi:
37. Kaczorowski GJ, Garcia ML, Bode J, Hess SD, Patel UA (2011) The importance of being profiled: improving drug candidate safety and efficacy using ion channel profiling. Front Pharmacol 2:78. doi:
38. Gribbon P, Sewing A (2003) Fluorescence readouts in HTS: no gain without pain? Drug Discovery Today 8:1035鈥?043. doi:
39. Parker LC, Prince LR, Sabroe I (2007) Translational mini-review series on Toll-like receptors: networks regulated by Toll-like receptors mediate innate and adaptive immunity. Clin Exp Immunol 147:199鈥?07. doi:
40. Nathans R, Cao H, Sharova N, Ali A, Sharkey M, Stranska R, Stevenson M, Rana TM (2008) Small-molecule inhibition of HIV-1 Vif. Nat Biotechnol 26:1187鈥?192. doi:
41. Clackson T (2000) Regulated gene expression systems. Gene Ther 7:120鈥?25. doi:
42. Gribbon P, Schaertl S, Wickenden M, Williams G, Grimley R, Stuhmeier F, Preckel H, Eggeling C, Kraemer J, Everett J, Keighley WW, Sewing A (2004) Experiences in implementing uHTS-cutting edge technology meets the real world. Curr Drug Discovery Technol 1:27鈥?5. doi:
43. Rogers D, Brown RD, Hahn M (2005) Using extended-connectivity fingerprints with Laplacian-modified Bayesian analysis in high-throughput screening follow-up. J Biomol Screen 10:682鈥?86. doi:
44. Daylight Chemical Information Systems Inc. (2005) Daylight Toolkit v4.91
45. Tripos Inc. (2005) DiverseSolutions
46. ThermoScientific. p://www.thermoscientific.com" class="a-plus-plus">http://www.thermoscientific.com. Accessed 26 Feb 2013 - 作者单位：Andrew S. Bell (1) (2)
Joseph Bradley (1) (3)
Jeremy R. Everett (1) (4)
Michelle Knight (1) (5)
Jens Loesel (1) (6)
John Mathias (1) (7)
David McLoughlin (1) (8)
James Mills (1) (9)
Robert E. Sharp (10) (11)
Christine Williams (1) (12)
Terence P. Wood (1) (13)
1. Pfizer Worldwide Research and Development, Sandwich, Kent, UK
2. Imperial College, London, UK
3. Scitegrity Ltd, Discovery Park, Sandwich, Kent, UK
4. University of Greenwich, Chatham Maritime, Kent, UK
5. Canterbury Christchurch University, Canterbury, Kent, UK
6. Peter Fisk Associates Limited, Canterbury, Kent, UK
7. Pfizer Research, Cambridge, MA, USA
8. Eli Lilly & Company, Indianapolis, IN, USA
9. Sandexis, Canterbury, Kent, UK
10. Pfizer Worldwide Research & Development, Groton, CT, USA
11. Intrexon Corporation, San Carlos, CA, USA
12. Kent and Canterbury Hospital, Canterbury, Kent, UK
13. TP & AAW Consultancy, Cliftonville, Kent, UK - ISSN：1573-501X
文摘
The screening files of many large companies, including Pfizer, have grown considerably due to internal chemistry efforts, company mergers and acquisitions, external contracted synthesis, or compound purchase schemes. In order to screen the targets of interest in a cost-effective fashion, we devised an easy-to-assemble, plate-based diversity subset (PBDS) that represents almost the entire computed chemical space of the screening file whilst comprising only a fraction of the plates in the collection. In order to create this file, we developed new design principles for the quality assessment of screening plates: the Rule of 40 (Ro40) and a plate selection process that insured excellent coverage of both library chemistry and legacy chemistry space. This paper describes the rationale, design, construction, and performance of the PBDS, that has evolved into the standard paradigm for singleton (one compound per well) high-throughput screening in Pfizer since its introduction in 2006.